Skip to main content

Table 3 Length of follow-up among IPF patients

From: Characterizing idiopathic pulmonary fibrosis patients using US Medicare-advantage health plan claims data

Cohorts Length of Follow-Up (in Years)
N % Mean (SD) Median Interquartile Range
IPF Cohort 4,716 100.0 1.3 (1.4) 0.8 0.2 - 1.8
Reason for Censoring:
 End of Study Period 1,537 32.6 1.8 (1.7) 1.3 0.5 - 2.7
 Death 1,082 22.9 0.9 (1.1) 0.5 0.1 - 1.4
 End of Health Plan Enrollment 1,289 27.3 1.2 (1.2) 0.9 0.3 - 1.8
 Exclusion Criteria Observed 808 17.1 0.8 (1.0) 0.4 0.1 - 1.1
IPF Diagnostic Testing Subgroup 2,518 100.0 1.2 (1.4) 0.7 0.2 - 1.7
Reason for Censoring:
 End of Study Period 793 31.5 1.8 (1.7) 1.2 0.5 - 2.7
 Death 584 23.2 0.9 (1.1) 0.4 0.1 - 1.2
 End of Health Plan Enrollment 661 26.3 1.2 (1.2) 0.8 0.3 - 1.8
 Exclusion Criteria Observed 480 19.1 0.7 (0.9) 0.3 0.1 - 1.0
  1. Optum Research Database – Medicare Advantage Population. Cohort Entry: 01 January 2008 - 30 September 2014
  2. Abbreviations: IPF idiopathic pulmonary fibrosis, SD standard deviation